沛嘉医疗-B(09996.HK)获首席执行官兼董事长张一增持不超过1500万港元公司股份 沛嘉医疗- B(09996.HK)：国家药监局受理GeminiOne®经导管缘对缘修复系统的注册申请 相关事件 格隆汇12月5日丨沛嘉医疗-B(09996.HK)公告，董事会获悉，张一透过其所控制的公司，自2025年12月1 日起开始于公开市场上购买公司股份(「持股增加」)。持股增加合共代价预期不超过1500万港元。 ...

经张博士告知，持股增加反映其对公司内在价值的认可，以及其对公司发展前景及增长潜力的坚定信 心。张博士将不排除根据适用法律及法规于适当时候进一步增加其于公司持股的可能性。 智通财经APP讯，沛嘉医疗-B(09996)发布公告，董事会获悉，执行董事、首席执行官兼公司董事会董事 长张一博士透过其所控制的公司，自2025年12月1日起开始于公开市场上购买公司股份。持股增加合共 代价预期不超过1500万港元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Peijia Medical Limited 沛嘉醫療有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9996） 自願公告 執行董事、首席執行官兼董事會董事長的持股增加 本公告乃由沛嘉醫療有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願作出，以告知本公司股東及潛在投資者有關執行董事、首席執行官兼本公司 董事會（「董事會」）董事長張一博士（「張博士」）於本公司持股增加的事宜。 董事會獲悉，張博士透過其所控制的公司，自2025年12月1日起開始於公開市 場上購買本公司股份（「持股增加」）。持股增加合共代價預期不超過15,000,000 港元。 經張博士告知，持股增加反映其對本公司內在價值的認可，以及其對本公司發 展前景及增長潛力的堅定信心。張博士將不排除根據適用法律及法規於適當 時候進一步增加其於本公司持股的可能性。 根據本公司可獲得的資料及就董事會所知 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 沛嘉醫療有限公司 (「本公司」)（於開曼群島註冊成立的有限公司） 呈交日期: 2025年12月2日 本月底法定/註冊股本總額： USD 100,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09996 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 671,438,159 | | 0 | | 671,438,159 | | 增加 / 減少 (-) | | | | 0 | | 0 | | | | 本月 ...

Core Insights - The neurovascular intervention medical consumables market in China is rapidly growing, with a projected market size of 132.56 billion yuan in 2024 and an expected increase to 197.22 billion yuan by 2025, indicating a significant growth trajectory in this sector [1][3]. Market Overview - The neurovascular intervention medical consumables market is categorized into three main segments: hemorrhagic intervention consumables (71.36 billion yuan, 53.83%), ischemic intervention consumables (35.04 billion yuan, 26.43%), and access intervention consumables (26.16 billion yuan, 19.73%) for 2024 [1][4]. - By 2025, the market shares are expected to shift slightly, with hemorrhagic intervention consumables projected to reach 109.95 billion yuan (55.75%), ischemic intervention consumables at 48.79 billion yuan (24.74%), and access intervention consumables at 38.48 billion yuan (19.51%) [1][4]. Industry Development - The neurovascular intervention field is recognized as a revolutionary advancement in neuroscience, providing less invasive treatment options compared to traditional open surgeries [3]. - The market has grown from 32.25 billion yuan in 2017 to 132.56 billion yuan in 2024, showcasing a robust annual growth rate [3]. Competitive Landscape - The market has historically been dominated by international giants such as Medtronic and Stryker, which held over 60% of the market share [5]. - Domestic companies like MicroPort NeuroScience, Xinwei Medical, Guichuang Tongqiao, and Peijia Medical have made significant advancements in product development, particularly in thrombectomy stents and embolization coils, enhancing their market competitiveness [5]. Industry Trends - The neurovascular intervention medical consumables industry is experiencing rapid growth driven by increased healthcare investment, rising consumer payment capabilities, and an aging population [7]. - There is a notable trend towards domestic companies achieving breakthroughs in lower-tech areas, with expectations for expansion into more advanced fields such as flow-directed devices and intracranial drug balloons [7].

Core Insights - The endovascular neurointervention for cerebral infarction has experienced explosive growth in China, driven by an aging population and lifestyle changes, leading to a continuous rise in the incidence of cerebral infarction [1][4][12] - The number of endovascular neurointervention procedures is projected to increase significantly, reaching 182,500 in 2024 and 266,600 in 2025 [1][5][4] Industry Definition and Barriers - Cerebral infarction, or acute ischemic stroke (AIS), accounts for approximately 80% of all strokes, primarily affecting individuals aged 45 to 70, with an increasing proportion of younger patients [2][4] - The industry has significant talent and brand barriers, as it requires specialized medical knowledge and substantial funding for product development and market entry [3][4] Current Industry Development - The endovascular neurointervention market has seen a rise from 24,100 procedures in 2017 to 182,500 in 2024, with expectations to reach 266,600 by 2025 [4][5] - The breakdown of procedures in 2024 includes intracranial stent retrieval (84,400 procedures, 46.25%), intracranial thrombectomy (66,500 procedures, 36.44%), and other procedures (31,600 procedures, 17.32%) [5] Industry Chain Structure - The industry chain includes upstream raw materials, production and diagnostic equipment, and professional support services, which influence the overall operation of the midstream device manufacturing and downstream clinical treatment [4][6] Major Companies - Key players in the market include Weikang Medical, Xinyi Medical, and Guichuang Tongqiao, among others, with increasing competition as demand grows [8][9] - Microinvasive Brain Science has established a comprehensive product line for stroke intervention, achieving significant revenue growth from 80 million yuan in 2019 to 402 million yuan in 2024 [9] - Guichuang Tongqiao reported a revenue of 780 million yuan in 2024, a 48.3% increase year-on-year, with a gross profit of 560 million yuan [9][10] Industry Development Trends - The market is expected to grow due to rising economic levels, lifestyle changes, and an aging population, with significant opportunities for domestic device manufacturers [12][13] - The industry is expanding its application range, moving beyond ischemic and hemorrhagic strokes to include complex lesions and combinations with other treatment methods [12][13]

Core Insights - The article emphasizes the global competition centered around "embodied intelligence" that has fully commenced by 2025, highlighting advancements in robotics and AI integration across various countries and companies [1][2] - It notes that 2025 marks a pivotal year for China's robotics industry, showcasing the growth of leading Chinese companies and innovative startups that are making significant contributions to the global supply chain [1][2] Industry Trends - The concept of "embodied intelligence" is becoming mainstream, transitioning from laboratory research to practical applications in various industries, indicating a shift from "software intelligence" to "embodied intelligence" [2] - The demand in the robotics market is evolving from "scale application" to "high-quality development," with a focus on collaborative intelligent agents capable of multi-scenario decision-making [2] Event Highlights - The Sixth China Robotics Industry Annual Conference is scheduled for December 18-19, 2025, in Hangzhou, aiming to serve as a critical gathering for the industry to mobilize towards the "embodied intelligence" era [3] - The conference will feature discussions on the strategic needs of companies, providing a platform for listed companies to enhance their market value and for pre-IPO companies to accelerate their listing processes [6][7] Strategic Insights - The event will release authoritative rankings such as "Top 50 Leading Chinese Robotics Companies," which will serve as a credibility booster for listed companies and a significant asset for those seeking to go public [6][7] - The conference will address the balance between specialized and general-purpose robotics, exploring how companies can position themselves in the evolving landscape of embodied intelligence [9][10] Value Proposition - The conference aims to not only witness industry changes but also actively shape the future of the robotics sector through resource allocation and ecosystem integration [11][13] - It will facilitate direct interactions between companies and key decision-makers from government, large enterprises, and investment institutions, promoting strategic partnerships and investments [13] Agenda Overview - The two-day agenda will include expert reports on technological breakthroughs and discussions on practical methodologies for industry leaders, ensuring a comprehensive understanding of the current and future landscape [14][15] - Interactive sessions and exhibitions will provide opportunities for showcasing cutting-edge technologies and fostering collaboration among industry participants [15]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 沛嘉醫療有限公司 (「本公司」)（於開曼群島註冊成立的有限公司） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09996 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | 100,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | 100,000 | 本月 ...

Major Events - Yuan Da Zhu Gong (02163) plans to apply for bankruptcy reorganization at Changsha Intermediate People's Court [1] - Yi Li Holdings (00076) subsidiary intends to issue blockchain vouchers V76, redeemable for bulk commodities on the platform [1] - Peijia Medical-B (09996): National Medical Products Administration accepts registration application for GeminiOne® transcatheter edge-to-edge repair system [1] - Paggen Biopharmaceutical-B (02565) proposes to grant exclusive license for VISEPEGENATIDE (PB-119) in the Middle East and Africa [1] - Beijing Enterprises Environment Group (00154) bids for Hong Kong I·PARK 2 project [1] - Fangda Holdings (01521) plans to acquire Shanghai Guanhua Medical Technology Co., Ltd. for 270 million yuan to enhance global laboratory service capabilities [1] - Lianzhong (06899) focuses on female user value, driving new entertainment through content [1] - Global New Materials International (06616) increases stake in CQV to 50.75%, strengthening global business collaboration [1] - Qianxin Biotechnology-B (02509): Qianxin's industrialization base successfully passes EU QP audit [1] - China Energy Construction (03996) subsidiary signs three new energy general contracting agreements, totaling approximately 19.554 billion yuan [1] - Yongyi International (01218) plans to sell all issued shares of Zhuoyi to Gaoshan (00616) [1] - Bohai Bank (09668) plans to list high capital-occupying debt assets for sale, with an initial pricing of no less than 48.883 billion yuan [1] - Chuangsheng Holdings (02680) plans to receive a premium of about 6% for full acquisition offer, resuming trading on October 13 [1] - Kelun-Botai Biopharmaceutical (06990): Core product TROP2ADC, Lukan-Satuzi (SAC-TMT) approved by National Medical Products Administration for third indication, treating EGFR mutation non-small cell lung cancer after EGFR-TKI progression [1] Operating Performance - Zhaojin Mining (01818) reports net profit of approximately 2.117 billion yuan for the first three quarters, a year-on-year increase of 140.43% [2] - Sunny Optical Technology (02382): September mobile phone camera module shipments reach 48.524 million units, a month-on-month increase of 15.3% and a year-on-year increase of 32% [2] - Yuexiu Property (00123) reports cumulative contract sales of approximately 79.812 billion yuan for the first nine months, a year-on-year increase of about 2.8% [2] - Qiu Tai Technology (01478) reports September camera module sales of 46.654 million units, a month-on-month decrease of 7.6% but a year-on-year increase of 45.1% [2]

Core Viewpoint - The company has received confirmation from the National Medical Products Administration regarding the acceptance of its registration application for the GeminiOne® transcatheter edge-to-edge repair (TEER) system [1] Group 1: Product Innovation - GeminiOne® is an internally developed innovative TEER device featuring a unique sliding groove mechanical structure that maintains a smaller implant size and delivery system while achieving a longer grasping arm length [1] - The device includes innovative features such as an independent leaflet capture function that reduces surgical complexity, an automatic locking mechanism to prevent repeated locking and unlocking during the procedure, and a multi-angle release design that accommodates a wider range of anatomical structures [1]